[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633078":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":26,"responsibleParty":42,"collaborators":46,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":62,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Azienda Ospedaliera Brotzu","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"HAHD Registry Cohort",null,"Adult patients with end-stage kidney disease undergoing maintenance hemodialysis and enrolled in the ICHARUS prospective observational registry. Patients are included based on the presence of persistent uremic symptoms and a clinical decision to use hemodialysis combined with hemoadsorption as part of routine care. All participants are followed longitudinally according to standard clinical practice.",[13],{"name":14,"affiliation":15,"role":16},"Claudio Ronco, MD","International Renal Research Institute of Vicenza","STUDY_DIRECTOR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Matteo Floris, MD","CONTACT","*393207718720","matteo.floris@aob.it",{"name":24,"role":20,"phone":10,"phoneExt":10,"email":25},"Matteo Marcello, MD","matteo.marcello@aulss8.veneto.it",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":31,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"S.C.D.U. Nefrologia, Dialisi e Trapianto ARNAS G.Brotzu, Cagliari","RECRUITING","Cagliari","Italy","09100","IT",{"type":35,"coordinates":36},"Point",[37,38],9.11917,39.23054,{"lat":38,"lon":37},[41],{"name":19,"role":20,"phone":10,"phoneExt":10,"email":22},{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Matteo Floris","M.D. Nephrology, Dialysis and Transplantation Unit G. Brotzu Hospital of Cagliari - Assistant Professor (tenure-track) University of Cagliari",[47],{"name":48,"class":6},"International Renal Research Institute Vicenza","100633078","icharus-italian-cooperative-hemoadsorption-study-for-relief-of-uremic-symptoms-100633078",false,"NCT07522008","ICHARUS: Italian Cooperative HemoAdsorption Study for Relief of Uremic Symptoms","ICHARUS: Italian Cooperative HemoAdsorption Study for Relief of Uremic Symptoms. A Prospective Observational Cohort Study to Assess the Effectiveness and Safety of Hemoadsorption in Chronic Hemodialysis Patients With Refractory Uremic Symptoms: An Italian Real-World Registry.","ICHARUS","Inclusion Criteria:\n\n* Adult patients (≥18 years) with end-stage kidney disease (CKD stage 5D) on maintenance hemodialysis.\n* Stable hemodialysis treatment for at least 3 months prior to enrollment.\n* Presence of at least one moderate-to-severe uremic symptom, as identified by the Dialysis Symptom Index at screening.\n* Planned treatment with hemodialysis combined with hemoadsorption according to local clinical practice.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Acute illness, active infection, or hospitalization within 4 weeks prior to enrollment.\n* Planned kidney transplantation within the study follow-up period.\n* Life expectancy less than 6 months due to non-renal comorbid conditions.\n* Inability to complete patient-reported outcome questionnaires.\n* Participation in another interventional clinical study that could interfere with study outcomes.","ALL","18 Years",{"count":60,"type":61},120,"ESTIMATED","6 Months","OBSERVATIONAL","Background:\n\nMany patients receiving maintenance hemodialysis continue to experience persistent uremic symptoms, such as pruritus, fatigue, sleep disorders, reduced physical performance, and impaired quality of life, despite optimized dialysis prescriptions. Conventional dialysis techniques mainly rely on diffusion and convection and may be insufficient to remove certain uremic toxins, particularly protein-bound and middle-molecule solutes.\n\nPurpose:\n\nThe ICHARUS study (Italian Cooperative HemoAdsorption Study for Relief of Uremic Symptoms) is a prospective, observational, real-world registry designed to evaluate the clinical use of hemodialysis combined with hemoadsorption (HAHD) in patients with persistent uremic symptoms.\n\nStudy design:\n\nICHARUS is a multicenter registry enrolling adult patients on maintenance hemodialysis in whom hemoadsorption is prescribed according to routine clinical practice. Hemoadsorption is added to standard dialysis sessions without modifying the underlying dialysis modality or prescription. The study does not involve randomization or experimental interventions.\n\nOutcomes:\n\nThe registry will collect data on patient-reported symptoms, quality of life, selected laboratory parameters, and safety outcomes at baseline and during follow-up at 1, 3, and 6 months. The aim is to describe symptom evolution, tolerability, and real-world treatment patterns associated with HAHD.\n\nSignificance:\n\nBy collecting standardized real-world data across multiple centers, the ICHARUS registry aims to improve understanding of the potential role of hemoadsorption in chronic hemodialysis, support harmonization of clinical practice, and generate hypotheses for future interventional studies.",[66,67],"Chronic Kidney Disease 5D","Uremia; Chronic",[69,70,71,72,73,74,75,76,77],"Hemoadsorption","Hemodialysis","HAHD","Protein-bound uremic toxins","Middle molecules","Uremic symptoms","Patient-reported outcomes","Quality of life","Real-world registry","2026-04-20",{"date":80,"type":81},"2026-04-21","ACTUAL",{"date":83,"type":81},"2026-03-15",{"date":85,"type":61},"2027-07",{"name":5,"class":6},1]